On October 26, the work of the Ralph Lauren Center for Cancer Care (RLCCC) was highlighted on ABC’s Good Morning America. RLCCC is a recipient of ASCO’s Quality Improvement Grant and a member of the 2016-17 Quality Training Program class.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On October 24, 2016, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.
This is the first FDA approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval also expands the indication in second-line treatment of lung cancer to include all patients with PD-L1-expressing NSCLC.
The FDA approval added the following indications for pembrolizumab:
In late September, the Centers for Medicare and Medicaid Services (CMS) released the 2015 Physician Quality Reporting System (PQRS) Feedback Reports and 2015 Annual Quality and Resource Use Reports (QRURs). These reports are used to determine whether a practice will receive bonuses or be subject to PQRS and Value Modifier payment penalties in 2017.
ASCO sent a letter to leaders in Congress urging them to advance the 21st Century Cures Act when Congress returns into session later this year to accelerate the discovery, development, and delivery of promising new treatments to patients.
Robert Miller, MD, FASCO, FACP, and CancerLinQ Medical Director, is the featured guest in the latest Journal of Oncology of Practice (JOP) Podcast with host and podcast editor Dr. Nathan Pennel.
“ASCO is concerned by the number of cancer deaths that continue to be caused by cigarette smoking in the United States, as revealed in the American Cancer Society’s study on state-level cancer mortality attributed to cigarette smoking. This research shows that approximately one-third of cancer deaths in men and one-quarter in women were associated with cigarette smoking. Of particular concern is the high proportion of cigarette-related cancer deaths in southern states.
CancerLinQ LLC, a wholly-owned nonprofit of the ASCO, has announced that more than one million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.
On Thursday, October 27, at 1:00 PM (EDT), SAP will co-host a webinar with Oxford Economics, “Healthcare Gets Personal,” and CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong will be on the panel, discussing CancerLinQ™.
On October 19, 2016, the U.S. Food and Drug Administration granted accelerated approval to olaratumab (LARTRUVO, Eli Lilly and Company) for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate.
On October 19, ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, gave the Commission on Cancer Oncology Lecture at the American College of Surgeons (ACS) Clinical Congress 2016.
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a one-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and impact patients with cancer and their care teams.
On October 18, 2016, the U.S. Food and Drug Administration modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations.
On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.
The Centers for Medicare and Medicaid Services (CMS) has launched their 30-day preview period for Physician Compare. Physician Compare is the website created by CMS to house publically reported performance scores for clinicians and group practices that provide Medicare services.
On October 14, the Office of the National Coordinator for Health Information Technology (ONC) published its final rule on its Health IT (HIT) Certification Program. The rule, “ONC Health IT Certification Program: Enhanced Oversight and Accountability,” finalizes modifications and new requirements under the ONC HIT Certification Program.